文献速递流行病学与生物统计临床试验与 GCP

当前药物干预性临床试验的全球化:2011至2013年的特征及相关因素

Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011-2013.
PubMed 文献 · Trials · 2017-06-21

研究从ClinicalTrials.gov提取30个国家2011至2013年的试验数据,比较10个代表性国家与美国的设计要素,并用多元线性回归分析试验点分布的相关因素。结果显示美国、德国、法国、加拿大和英国为试验数量前五的国家;印度1期试验更常见,9个代表性国家3期试验均较美国更普遍;人均医疗支出、经济自由指数、人力资本指数和知识产权指数可解释区域分布方差63.6%。

要点

  • 美国、德国、法国、加拿大和英国是临床试验数量最多的前五个国家。
  • 印度1期试验比美国更常见(OR 1.517,p<0.001),9个代表性国家3期试验均比美国更普遍。
  • 人均医疗支出、经济自由指数、人力资本指数和知识产权指数可解释区域分布方差63.6%。

核心结论

  • 亚洲、南非和东欧等新兴地区的临床试验全球化与经费驱动、招募人群和监管约束等因素并行发展。

研究设计与样本

  • 从ClinicalTrials.gov网站提取30个国家的试验数据要素,包括「期别」、「招募状态」、「申办者类型」、「年龄组」和「试验设计」。
  • 选取包括美国在内的10个洲代表性国家,并将其设计要素与美国进行比较。
  • 选择与试验点分布相关的因素进行多元线性回归分析。

主要发现

  • 美国、德国、法国、加拿大和英国是频繁开展临床试验的前五个国家。
  • 9个洲代表性国家的设计要素与美国有较大差异;印度1期试验更常见(OR 1.517,p<0.001)。
  • 9个代表性国家的3期试验均比美国更普遍。
  • 波兰(OR 1.852,p<0.001)、以色列(OR 1.546,p=0.005)和南非(OR 1.963,p<0.001)的「儿童」年龄组试验数量多于美国。
  • 多元分析显示,人均医疗支出、经济自由指数、人力资本指数和知识产权指数可解释临床试验区域分布方差的63.6%。

关键数值与推荐

  • 印度1期试验相比美国的OR为1.517(p<0.001)。
  • 波兰「儿童」年龄组试验相比美国的OR为1.852(p<0.001)。
  • 以色列「儿童」年龄组试验相比美国的OR为1.546(p=0.005)。
  • 南非「儿童」年龄组试验相比美国的OR为1.963(p<0.001)。
  • 人均医疗支出、经济自由指数、人力资本指数和知识产权指数可解释区域分布方差63.6%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trial globalization is a major trend for industry-sponsored clinical trials. There has been a shift in clinical trial sites towards emerging regions of Eastern Europe, Latin America, Asia, the Middle East, and Africa. Our study objectives were to evaluate the current characteristics of clinical trials and to find out the associated multiple factors which could explain clinical trial globalization and its implications for clinical trial globalization in 2011-2013. METHODS: The data elements of "phase," "recruitment status," "type of sponsor," "age groups," and "design of trial" from 30 countries were extracted from the ClinicalTrials.gov website. Ten continental representative countries including the USA were selected and the design elements were compared to those of the USA. Factors associated with trial site distribution were chosen for a multilinear regression analysis. RESULTS: The USA, Germany, France, Canada, and United Kingdom were the "top five" countries which frequently held clinical trials. The design elements from nine continental representative countries were quite different from those of the USA; phase 1 trials were more prevalent in India (OR 1.517, p < 0.001) while phase 3 trials were much more prevalent in all nine representative countries than in the USA. A larger number of "child" age group trials was performed in Poland (OR 1.852, p < 0.001), Israel (OR 1.546, p = 0.005), and South Africa (OR 1.963, p < 0.001) than in the USA. Multivariate analysis showed that health care expenditure per capita, Economic Freedom Index, Human Capital Index, and Intellectual Property Rights Index could explain the variance of regional distribution of clinical trials by 63.6%. CONCLUSIONS: The globalization of clinical trials in the emerging regions of Asia, South Africa, and Eastern Europe developed in parallel with the factors of economic drive, population for recruitment, and regulatory constraints.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jeong S, Sohn M, Kim JH, et al. Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011-2013. Trials. 2017. PMID: 28637515. doi:10.1186/s13063-017-2025-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。